Reports Q2 revenue $2.1M vs. $2.5M last year. “We made substantial progress on our pipeline during Q2 2023 with the initiation of Phase 1/2a clinical trials for VMT-alpha-NET for neuroendocrine tumors and VMT01 for melanoma and we expect preliminary results from initial cohorts by end of the year,” said Thijs Spoor, Perspective Therapeutics’ CEO. “We are supplying both U.S. trials with drug product from our GMP manufacturing facility in Coralville, Iowa. We expect to bring additional CDMO manufacturing sites online in the coming months to enable broader coverage of sites across the U.S. Isotope will be supplied using Perspective’s proprietary VMT-alpha-GEN 212Pb benchtop generator.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CATX:
- Perspective Therapeutics Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of VMT01 of its Targeted Alpha-Particle Therapy (TAT), for Treatment of MC1R-positive Metastatic Melanoma
- Perspective Therapeutics Reports Second Quarter Fiscal 2023 Results and Recent Business Highlights
- Perspective Therapeutics, GT Medical Technologies enter collaboration
- Perspective Therapeutics and GT Medical Technologies Collaborate to Expand Access to Unique Cesium-131 Based Brain Cancer Treatment
- Perspective Therapeutics’ Cesium-131 featured at ABS conference